Collectively, our findings suggest that HSD3B1 is upregulated in LTED and tamoxifen-treated breast cancer cells, enhancing DHEA metabolism, sustaining ER signaling, and promoting cell survival. This evidence concerns the gene HSD3B1 and breast cancer.